
From Osaka to America: The Unconventional Journey of This Japanese Entrepreneur
When business leader Hideaki Nishioka left his stable corporate job in Japan to pursue entrepreneurship in the United States, his decision was met with confusion and resistance from his family and colleagues.
Opinions expressed by Entrepreneur contributors are their own.
You're reading Entrepreneur Asia Pacific, an international franchise of Entrepreneur Media.
The decision to strike out and try something new is rarely an easy one, especially when it also involves defying convention and the risk of disappointing those closest to you. The start of any journey is often accompanied by a good deal of stress and uncertainty, but when a singular vision is paired with a bit of good fortune, exciting things are rarely far behind.
When business leader Hideaki Nishioka left his stable corporate job in Japan to pursue entrepreneurship in the United States, his decision was met with confusion and resistance from his family and colleagues. Born and raised in Osaka, he had spent his entire life up until that point in elite academic institutions and prestigious roles at global firms like Itochu Corporation.
Yet, deep down, he knew he was meant for something more than just climbing the corporate ladder.
Instead of following the path expected of him, Nishioka took a bold leap into the unpredictable world of entrepreneurship. His journey took him from Tokyo to Vancouver, factories in Italy to an MBA program in California, and ultimately to the heart of the American restaurant industry.
Today, he is the CEO of Tokyo Shokudo Holdings, a company on a mission to redefine Japanese dining in the U.S., making high-quality, authentic Japanese cuisine more accessible to everyday consumers.
But Hideaki Nishioka's story isn't just about building a restaurant empire—it's about challenging conventions, embracing risk, and proving that success often lies down the roads less traveled. Nishioka dared to step outside tradition, blending Eastern discipline with Western entrepreneurial spirit to create something truly remarkable.
A Road Less Traveled: Making of an International Trailblazer
Nishioka was born in Osaka, Japan, and grew up with his big sister, a smart and industrious girl he adored. He would follow her around and read her school textbooks, and the two formed a friendly rivalry which inspired Nishioka to strive for academic excellence and exceed expectations.
He attended Rakunan Junior High and High School, a prestigious institution in Kyoto built on a UNESCO World Heritage Site, To-ji Temple, before studying at Keio University in Tokyo, one of Japan's top business schools, focusing on financial engineering.
But while tradition was the name of the game at his schools, with the vast majority of students pursuing careers in engineering and medicine, Nishioka had big dreams and took a gap year to study business in Vancouver, Canada.
In Canada, he broadened his horizons by taking business management courses and developed a deep appreciation of how business is done internationally. With the understanding of Western business philosophies that this experience gave him, he went on to intern at multiple global firms, including Morgan Stanley, McKinsey, and PwC.
"I learned that there is a critical difference between operating a company and managing employees between Japan and the U.S.," Nishioka revealed. "My passion is to unite the management techniques of these two countries and tailor them to the situation."
With the fire of entrepreneurship lit, Nishioka turned down a promising job offer from Goldman Sachs in favor of Itochu Corporation, one of Japan's largest trading firms, attracted by its diversity and the chance to fully engage in international business as a manager.
The entire global team at Itochu were much more experienced than Nishioka, but he built a strong rapport with them by always being respectful and suggesting clear, well-thought out ideas to gain their trust in him, which eventually led to his remarkable achievements at the organization.
The Leap to Entrepreneurship and U.S. Expansion
Even a dream job can be outgrown, and this was Nishioka's experience with Itochu. His time there was extremely valuable, and he maintains strong relationships with his former team and managers, but Nishioka was ready to challenge himself away from Itochu and continue exploring the world outside Japan.
Determined to expand his business acumen beyond corporate life, Hideaki enrolled at UCLA Anderson School of Management, specializing in entrepreneurship and investment management. His venture capital experience at K Fund Capital Management in Los Angeles during his MBA helped Nishioka co-found 3D Architech, a metal 3D printing company, and secure venture capital funding after prestigious accelerator programs like Mass Challenge and CleanTech Open.
After realizing that the majority of the time at startups is spent securing funding, Nishioka refocused his efforts on aligning himself with a cash-flow-driven business where he could apply his management skills. Good fortune struck, and Nishioka was introduced to the founder of Tokyo Shokudo Group, which operates several promising Japanese restaurant brands based in Texas and was looking to find its niche and establish itself as a force in the American dining scene.
This pivotal moment reinforced a key insight: long-term success isn't just about innovation—it's about choosing the right business model with the right members that aligns with your skills, goals, and market realities.
Building Tokyo Shokudo: A Vision for Japanese Dining in America
"One thing I noticed after I came to the U.S. was that all the people who went to Japan told me that the food in Japan was much better than the Japanese food in the U.S.," Nishioka recalls. "The opportunity I see is the 'better' and 'affordable' Japanese food. At Tokyo Shokudo, we offer home-style, authentic Japanese food without going to Japan."
Nishioka realized that many people in the United States ate at restaurants categorized as Japanese, but without developing an appreciation for what makes the food and the culture so unique. After conversations with the founder of Tokyo Shokudo Group, who wanted someone to help him refine and hone his vision of making Japanese cuisine accessible to the masses, Nishioka stepped in as CEO to take the business to the next level.
Tokyo Shokudo Group has since grown to eight locations (soon to be 11 in 2025) across California, Texas, and Illinois in the United States, with plans to reach 50 locations by 2030. Nishioka's growth strategy is focused on franchising, data-driven and customer-oriented site selection, and menu optimization that focuses on affordability and operational efficiency without sacrificing quality.
By offering a balance between authenticity and scalability, Hideaki and his team have positioned Tokyo Shokudo as the go-to brand for quality Japanese dining in the U.S.
Lessons for Aspiring Entrepreneurs
Hideaki Nishioka's unique experiences across Japan and America, strong drive to exceed expectations, and willingness to take on new and unexpected challenges have informed his successful approach to entrepreneurship, which emphasizes bold decision-making, adaptability, and the importance of cultural fusion in business success.
Even as he continues to build Tokyo Shokudo into a globally recognized brand, he remains as committed to his pursuit of excellence as he was as a young man. Ultimately, his message to other entrepreneurs is to take risks and challenge what others might expect, just as he did by leaving a corporate job to live out his entrepreneurial passion.
"If you follow the standard, you will be in the standard," Nishioka concludes. "If you want to be an outlier, you must carve your own path."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New York Post
19 minutes ago
- New York Post
Boeing 787 Dreamliner jet in Air India crash was subject of conspiracy theories about dead whistleblower — and battery problems
Thursday's Air India plane crash that killed more than 240 people has brought renewed scrutiny on Boeing's 787 Dreamliner aircraft — which was at the center of a conspiracy theory following a whistleblower's suicide last year. The disaster marks the first time a 787 Dreamliner — Boeing's newest plane model — has been involved in a catastrophic crash since its debut in 2011. It's also the latest disaster to hit the beleaguered American aerospace giant — which has been dogged by a door that blew off a 737 jet, a leaky spacecraft that stranded astronauts on the International Space Station for months, as well as politically damaging delays in outfitting the new Air Force One jets. The Dreamliner is Boeing's bestselling wide-body aircraft, and more than 1,200 have been delivered to airlines worldwide. Advertisement The deadly crash has left a stain on the jet's safety record heading into the Paris air show next week. Boeing's stock tanking by nearly 4.8% as CEO Kelly Ortberg scrambles to boost production of the Dreamliner. 6 A Boeing 787 Dreamliner operated by Air India crashed and exploded on Thursday morning, killing more than 240 people. Viral Press via Reuters Connect 6 First responders work at the site of the plane crash in Ahmedabad, India. Saurabh Sirohiya/NurPhoto/Shutterstock The Dreamliner was first introduced on Japan's All Nippon Airways in 2011 and there are more than 30 operated by Air India today, according to Cirium, an aviation data firm. Advertisement The Air India jet that crashed on Thursday was built in 2014 and had performed some 8,000 takeoffs and landings, according to the Wall Street Journal. Despite enjoying a 14-year safety streak, the troubled aerospace giant has seen its Dreamliner suffer from a series of production woes and attention from whistleblowers warning about the massive plane's assembly. The issues began in 2013, with Boeing's fleet of 787s grounded following a series of battery fires flagged by air safety inspectors. Advertisement Boeing was also forced to pause all 787 deliveries for nearly two years until the summer of 2022 over quality concern issues. 6 Debris of the doomed Air India plane hands over the destroyed ceiling of a local building. REUTERS 6 The tragedy is the biggest aircraft disaster in India in nearly three decades. Saurabh Sirohiya/NurPhoto/Shutterstock The pause ended when the Federal Aviation Administration approved Boeing's plan to make fixes that included filling paper-thin gaps around the plane and replacing parts that were not made with the approved titanium needed. Advertisement Things only got worse for Boeing last year when whistleblowers began coming out, accusing the company of taking shortcuts to fill the gap created by the 2020 pause, with the former employees and engineers warning that the practice could cause premature damage to the planes. Boeing has repeatedly disputed the claims made by the whistleblower, claiming an internal investigation recovered no evidence to support the whistleblowers' concerns over the South Carolina factory where the Dreamliners are made. 6 Mourners gather in Patna to pray for the victims of the plane crash, were only one passenger reportedly survived. AFP via Getty Images 6 Boeing has more than 1,000 787-9 Dreamliners in operation around the world. Getty Images Among the whistleblowers was John Barnett, 62, who was found dead just a day after sitting for a deposition with the company's lawyers in March 2024. His death was ruled a suicide. Barnett's death triggered countless conspiracy theories targeted against Boeing, despite investigators finding no evidence of foul play involved in the former employee's death. Thursday's crash also comes as Boeing is still reeling from the deadly accidents involving its 737 Max plane, which saw 346 people die in crashes in 2018 and 2019. Advertisement The company had reached a deal with the Department of Justice last month to avoid taking criminal responsibility for the crashes. 'Our deepest condolences go out to the loved ones of the passengers and crew on board Air India Flight 171, as well as everyone affected in Ahmedabad,' Ortberg said in a statement following Thursday's tragedy.
Yahoo
30 minutes ago
- Yahoo
Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders
Meeting to Reconvene on Wednesday, July 9, 2025 SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced that the company's 2025 annual meeting of stockholders (the 'Annual Meeting') was convened and adjourned without any business conducted due to lack of the required quorum. A quorum is necessary to hold the Annual Meeting. There were fewer than a majority of shares entitled to vote present, either in person or by proxy, at the Annual Meeting. The Annual Meeting therefore had no quorum and was adjourned to allow time to solicit additional proxies on behalf of the company's board of directors. The Annual Meeting will reconvene at 9:00 a.m. Pacific Time on Wednesday, July 9, 2025, and will continue to be held virtually. Stockholders who have already submitted a proxy or voted do not need to vote again, as proxies and votes previously submitted in respect of the Annual Meeting will remain valid at the reconvened Annual Meeting unless properly revoked. The record date for determining stockholders eligible to vote at the reconvened Annual Meeting remains April 17, 2025. Stockholders as of close of business on the April 17, 2025 record date who have not yet voted are encouraged to vote online at or by telephone at 1-800-690-6903. Please vote by 11:59 p.m. Eastern Time on July 8, 2025. If you hold your shares of the company's common stock in an account at a brokerage firm, bank, dealer or other similar organization, you may be subject to an earlier voting deadline and you should carefully review any materials received from the organization holding those shares regarding how to vote to ensure your vote is counted. A copy of the company's definitive proxy statement for the Annual Meeting is available to stockholders on on the Company's website at and on the website maintained by the U.S. Securities and Exchange Commission ('SEC') at Daré Bioscience stockholders as of close of business on the April 17, 2025 record date for the Annual Meeting, or their legal proxy holders, will be able to attend the reconvened Annual Meeting by visiting Important Information This material may be deemed to be solicitation material in respect of the Annual Meeting to be reconvened and held on Wednesday, July 9, 2025. In connection with the Annual Meeting, the company filed a definitive proxy statement with the SEC on April 24, 2025. BEFORE MAKING ANY VOTING DECISION, THE COMPANY URGES ITS STOCKHOLDERS TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING. The definitive proxy statement was sent or made available to stockholders entitled to vote at the Annual Meeting on or about April 24, 2025. No changes have been made to the proposals to be voted on by stockholders at the Annual Meeting. A copy of the definitive proxy statement and any other materials filed by the company with the SEC can be obtained free of charge at the SEC's website at or the company's website at About Daré Bioscience Daré Bioscience is a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority. Daré believes that innovation does not have to start from scratch. The company's goal is to bring to market as soon as practicable innovative evidence-based solutions that address decades of unmet needs in women's health and enhance outcomes and convenience, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. The potential products Daré identifies, in many cases, already have clinical proof of concept or existing safety data for the active ingredient that the company leverages. This provides optionality and flexibility, in many cases, in how Daré seeks to bring solutions to market in ways designed to optimize access for women in a fiscally responsible manner. The first FDA-approved product to emerge from Daré's portfolio of women's health product candidates is XACIATO™ (clindamycin phosphate) vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Visit for information about XACIATO. Daré's portfolio also includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil citrate, the active ingredient in an oral erectile dysfunction drug for men, to treat female sexual arousal disorder (FSAD); and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy. To learn more about Daré's full portfolio of women's health product candidates and mission to deliver differentiated therapies for women, please visit Daré Bioscience leadership has been named on the Medicine Maker's Power List and Endpoints News' Women in Biopharma and Daré's CEO has been honored as one of Fierce Pharma's Most Influential People in Biopharma for Daré's contributions to innovation and advocacy in the women's health space. Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website ( SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré's website. Contacts: Daré Bioscience Investor Relationsinnovations@ Source: Daré Bioscience, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
Anteris Technologies Global (ASX:AVR) investors are sitting on a loss of 66% if they invested three years ago
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long term Anteris Technologies Global Corp. (ASX:AVR) shareholders know that all too well, since the share price is down considerably over three years. Regrettably, they have had to cope with a 66% drop in the share price over that period. And more recent buyers are having a tough time too, with a drop of 62% in the last year. The falls have accelerated recently, with the share price down 35% in the last three months. So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Anteris Technologies Global isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally hope to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit. In the last three years Anteris Technologies Global saw its revenue shrink by 24% per year. That means its revenue trend is very weak compared to other loss making companies. Arguably, the market has responded appropriately to this business performance by sending the share price down 18% (annualized) in the same time period. Bagholders or 'baggies' are people who buy more of a stock as the price collapses. They are then left 'holding the bag' if the shares turn out to be worthless. After losing money on a declining business with falling stock price, we always consider whether eager bagholders are still offering us a reasonable exit price. The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail). Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time. While the broader market gained around 14% in the last year, Anteris Technologies Global shareholders lost 62%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 8% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 5 warning signs for Anteris Technologies Global (3 don't sit too well with us) that you should be aware of. If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data